Dr. Bo Wang, MD

Medicare patients and services

Medicare patients, 2024

505

Services billed

129,971

Patients’ average age

73

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 19 companies reported 85 payments worth $84,023 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Oregon →

Industry-funded research

Named as a principal investigator on 10 industry-funded studies in 2025, from 8 companies. The companies reported $672,280 in research payments for these studies, mostly to the institutions running them.

• A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvaluma…
  Amgen Inc.
• A phase iii, randomized, open-label, multicenter study evaluating the efficacy and safety of divaras
  Genentech, Inc.
• ALI-4201
  Puma Biotechnology, Inc.
• A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line T…
  Janssen Research & Development, LLC
• A randomized phase 3 openlabel study to evaluate SGNB6A compared with docetaxel in adult subjects with previously treated nonsmall cell lung cancer
  Pfizer Inc.
• A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line T…
  Janssen Research & Development, LLC
• A phase iii, randomized, double-blind study of tira plus atezo in adjuvant nsclc
  Genentech, Inc.
• Brightline-2 PhIIa/IIb Brigimadlin mono in MDM2 amp tumors
  Boehringer Ingelheim Pharmaceuticals, Inc.
• Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
  Mirati Therapeutics, Inc. · Recruiting · NCT04613596
• KEYMAKER-U01 Substudy 01E# A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectab…
  Merck Sharp & Dohme LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Corvallis

• Peter D. Kenyon, M.D.
• Stephen V. Neville, MD
• Keith R. Wells, MD